Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pivonello

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Neuroendocrinology|April 23, 2004
Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogsC Matrone, R Pivonello, A Colao, et al.
Journal of Endocrinological Investigation|November 20, 2019
Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review studyA Colao, L F S Grasso, M Di Cera, et al.
Hormone Research in Paediatrics|January 10, 2014
Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1bD Melis, R Pivonello, M Cozzolino, et al.
Journal of Endocrinological Investigation|May 2, 2024
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's diseaseR Pivonello, M Fleseriu, J Newell-Price, et al.
Journal of Endocrinological Investigation|December 30, 2017
Correction to: Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|February 9, 2017
Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
European Journal of Neurology|April 5, 2013
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's diseaseM T Pellecchia, G Santangelo, M Picillo, et al.
Journal of Endocrinological Investigation|April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDYS Grottoli, A Bianchi, F Bogazzi, et al.
Andrology|June 13, 2019
Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico-Andrologo surveyD Gianfrilli, A Ferlin, A M Isidori, et al.
Endocrine|June 21, 2020
Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey databaseV Amodru, P Petrossians, A Colao, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Neuroendocrinology|April 23, 2004
Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogsC Matrone, R Pivonello, A Colao, et al.
Journal of Endocrinological Investigation|November 20, 2019
Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review studyA Colao, L F S Grasso, M Di Cera, et al.
Hormone Research in Paediatrics|January 10, 2014
Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1bD Melis, R Pivonello, M Cozzolino, et al.
Journal of Endocrinological Investigation|May 2, 2024
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's diseaseR Pivonello, M Fleseriu, J Newell-Price, et al.
Journal of Endocrinological Investigation|December 30, 2017
Correction to: Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|February 9, 2017
Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
European Journal of Neurology|April 5, 2013
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's diseaseM T Pellecchia, G Santangelo, M Picillo, et al.
Journal of Endocrinological Investigation|April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDYS Grottoli, A Bianchi, F Bogazzi, et al.
Andrology|June 13, 2019
Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico-Andrologo surveyD Gianfrilli, A Ferlin, A M Isidori, et al.
Endocrine|June 21, 2020
Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey databaseV Amodru, P Petrossians, A Colao, et al.
Pageof 14